Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Russano M, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K. Cortellini A, et al. Among authors: cantale o. Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21. Clin Lung Cancer. 2020. PMID: 32680806
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G. Cortellini A, et al. Among authors: cantale o. Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May 30. Cancer Immunol Immunother. 2020. PMID: 32474768 Free PMC article.
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
Banna GL, Signorelli D, Metro G, Galetta D, De Toma A, Cantale O, Banini M, Friedlaender A, Pizzutillo P, Garassino MC, Addeo A. Banna GL, et al. Among authors: cantale o. Transl Lung Cancer Res. 2020 Aug;9(4):1533-1542. doi: 10.21037/tlcr-19-583. Transl Lung Cancer Res. 2020. PMID: 32953525 Free PMC article.
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%.
Metro G, Banna GL, Signorelli D, Gili A, Galetta D, Galli G, Economopoulou P, Roila F, Friedlaender A, Camerini A, Christopoulou A, Cantale O, De Toma A, Pizzutilo P, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Giannarelli D, Mountzios G, Addeo A. Metro G, et al. Among authors: cantale o. J Immunother. 2020 Nov/Dec;43(9):299-306. doi: 10.1097/CJI.0000000000000340. J Immunother. 2020. PMID: 32991393
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.
Banna GL, Cantale O, Muthuramalingam S, Cave J, Comins C, Cortellini A, Addeo A, Signori A, McKenzie H, Escriu C, Barone G, Chan S, Hicks A, Bainbridge H, Pinato DJ, Ottensmeier C, Gomes F. Banna GL, et al. Among authors: cantale o. Int Immunopharmacol. 2022 Sep;110:108985. doi: 10.1016/j.intimp.2022.108985. Epub 2022 Jun 28. Int Immunopharmacol. 2022. PMID: 35777264 Free article.
International Survey on Frailty Assessment in Patients with Cancer.
Banna GL, Cantale O, Haydock MM, Battisti NML, Bambury K, Musolino N, O'Carroll E, Maltese G, Garetto L, Addeo A, Gomes F. Banna GL, et al. Among authors: cantale o. Oncologist. 2022 Oct 1;27(10):e796-e803. doi: 10.1093/oncolo/oyac133. Oncologist. 2022. PMID: 35905085 Free PMC article.
Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice.
Gagliano A, Prestifilippo A, Cantale O, Ferini G, Fisichella G, Fontana P, Sciacca D, Giuffrida D. Gagliano A, et al. Among authors: cantale o. Front Oncol. 2021 Jun 17;11:643155. doi: 10.3389/fonc.2021.643155. eCollection 2021. Front Oncol. 2021. PMID: 34221963 Free PMC article. Review.
13 results